Back to Journals Integrated Pharmacy Research and Practice Volume 14 Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity Authors Alzahrani AM, Alshobragi GA, Alshehri AM, Alzahrani MS, Alshehri HA, Alzhrani RM, Basudan S, Alkatheeri AA, Almutairi SA, Alzahrani YA Received 12 November 2024 Accepted for publication 13 March 2025 Published 6 April 2025 Volume 2025:14 Pages 5972 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Walid Al-Qerem Abdullah M Alzahrani, 1 3 Ghada A Alshobragi, 1 Abdullah M Alshehri, 1 Majed S Alzahrani, 1 Hasan A Alshehri, 1 Rami M Alzhrani, 4 Samah Basudan, 5 Ayed A Alkatheeri, 6 Salman A Almutairi, 7 Yahya A Alzahrani 2, 6 1 Pharmaceutical Care Department, Ministry of National GuardHealth Affairs, Jeddah, 22384, Saudi Arabia
Clinical data shows GI symptoms are most common early and decline noticeably with continued use
It prevents the formation of advanced glycation end products (AGEs), which contribute to age-related diseases, such as diabetes, cardiovascular disease, and neurodegenerative disorders (Nagai et al., 2012)
When combined with semaglutide therapy from PlexusDx, genetic guidance creates a truly personalized nutrition strategynot a one-size-fits-all approach
The side effects are generally the same whether you take Ozempic for type 2 diabetes or weight loss
Peptide drugs in the early 1990s were considered impractical
